SINCE 2014, SEN-JAM HAS BEEN ON A MISSION TO REVOLUTIONIze pain management - AND usher in a new dawn for humanity... FULL-STRENGTH LIVING
Sen-Jam has been working hard building strategic partnerships, driving momentum and amassing 45 both domestic and international patents and patents pending
-
July 2023
Article Published
How A Rebirth Towards Preventing Inflammation Will Positively Impact Age-Related Diseases in Pharmacy Times by Jackie Iversen RPh MS
-
June 2023
Fireside Chat for Investor Insight
Angelspan Founder Joe Milam and SJP CEO, Jim Iversen sit down to discuss the Best Startup Practices. To watch the 30-minute chat in full, click HERE.
-
June 2023
Intellectual Property Update
Secured two more patents worldwide with Mexico and Israel for SJP001 (Alcohol Hangover Prevention therapeutic)
-
June 2023
Industry Events
The Sen-Jam team embarked on trips to BIO 2023 in Boston and the Age-Related Diseases Summit in San Francisco.
-
May 2023
Meet the Founder Webinar
World-renowned Physicist, Investor and Advisor, Alexander Wissner-Gross hosts a Sen-Jam Pharma Webinar. See it HERE.
-
April 2023
International Speaking Event
Jackie Iversen RPh, MS, Founder, and Chief Clinical Officer was a speaker at the 13th Annual Alcohol Hangover Research Convention held in Dresden, Germany
-
April 2023
Article Published
Connecting the Dots of Alcohol Hangover, Inflammation and Age-Related Diseases in Pharmacy Times by Jackie Iversen, RPh MS
-
April 2023
Intellectual Property Update
Granted patent for SJP-001 in New Zealand. This secures our hangover prevention beachhead in the United States, European Union, Japan, Australia, South Africa, and New Zealand. We are still prosecuting in China, Korea, Brazil, Mexico, Canada, and Israel
-
March 2023
SJP Sponsoring Students at Northeastern
Students involved in the Capstone Project at Northeastern University presented their final reports to the Sen-Jam Team
-
February 2023
Intellectual Property Update
Entered the national phase with our Oral COVID-19 therapeutic patent, USA, Europe, Japan, China, South Korea, Australia, Canada, Mexico, Brazil, India, Israel, South Africa, Singapore, and New Zealand.
-
January 2023
JP Morgan 41st Annual Conference
Jackie Iversen RPh, MS, spoke at the 41st Annual JP Morgan Health Conference in San Francisco. and the Team met with many interested investors.
-
December 2022
Sen-Jam Anthem Video
The Power of Being a Change Agent. Click HERE
-
November 2022
Fireside Chat with Real Leaders
Sen-Jam CEO, Jim Iversen shares the mic with Kiran Vepuri, KVK Tech's VP of Business Development. "ARE YOU A DISRUPTER?" fireside chat on the power of collaboration and innovative thinking to get things done faster and more efficiently, together. To see Kiran's quick 4-minute recap from this event, click HERE.
-
October 2022
Article Published
The Balancing Act of Vaccines ion Pharmacy Times by Jackie Iversen RPh MS
-
October 2022
Capital Campaign
Launch on STARTENGINE for Series A Funding open to both Individual and Institutional Investors
-
September 2022
-
August 2022
-
June 2022
Webinar
Investor Roundtable Webinar with Distinguished Panelists
-
May 2022
Clinical Trail Commences
Clinical Trial Enrollment Officially Underway in Nepal for our COVID-19 Therapeutic
-
May 2022
SJP Team News
Neal Zahn joins SJP Team as esteemed Global Director of Licensing
-
May 2022
Intellectual Property Update
Alcohol Hangover Prevention asset SJP-001 awarded European Patent
-
April 2022
Article Published
Alcohol Hangover is newly Classified: Treatable Disease Article by Jackie Iversen RPh MS, in Pharmacy Times
-
March 2022
Press Release
SJP enters Powerful Partnership with CMC
expert, KVK-Tech -
February 2022
Press Release
-
January 2022
Milestone
WeFunder milestone! Pharma for the People proves viable! Sen-Jam raises $500K from 172 investors.
-
January 2022
-
January 2022
National Pharmacist Day: Op-Ed
Here's the Real Reasons a COVID-19 Infection is So Tough to Manage
2022
-
December 2021
-
October 2021
COVID-19 Phase II Clinical Trial Secured
Press Release: Sen-Jam Pharmaceutical secures Phase II Clinical Trial for COVID therapy SEN-JAM PR Oct 12 2021 Pill for COVID treatment Trials
-
September 2021
Intellectual Property Update
In support of Sen-Jam's mission to improve societal well-being, our Patent Application No. 11,129,803B2 for Methods and Compositions to Inhibit Tolerance to Opioids was granted by the United States Patent and Trademark Office on September 28th.
-
September 2021
Novel Solutions for Addressing Traditional Treatment Deficits
Press Release: Sen-Jam Pharmaceuticals addresses deficits with traditional treatments for COVID-19 as well as OPIOID WITHDRAWAL SEN-JAM PR Sept 28 2021 COVID Treatment
-
August 2021
-
July 2021
Mid-Year Stakeholder Update
-
May 2021
Intellectual Property Update
Australian Patent Granted AU2016235484B2 for Methods and Compositions to Inhibit Symptoms Associated with Veisalgia (SJP-001) (Alcohol Hangover Prevention)
-
May 2021
Intellectual Patent Update
Japan Patent Granted JP6851365B2 for Methods and Compositions to Inhibit Symptoms Associated with Veisalgia (SJP-001) (Alcohol Hangover Prevention)
-
April 2021
Intellectual Patent Update
South Africa Patent Granted 201706794B for Methods and Compositions to Inhibit Symptoms Associated with Veisalgia (SJP-001) (Alcohol Hangover Prevention)
-
March 2021
COVID-19 Research Paper Published
-
February 2021
Licensing Update
Sen-Jam has executed a licensing term sheet with Haltzak Biopharma for SJP-002C (COVID-19 Treatment) for Colombia with expansion rights to Central and South America.
-
February 2021
Intellectual Patent Update
Received Notice of Patent Allowance from the Japanese Intellectual Patent Office for SJP-001 (Alcohol Hangover Prevention)
Received Notice of Acceptance from the Australian Patent Office for SJP-001 (Alcohol Hangover Prevention)
-
February 2021
Opioid Withdrawal Research Papers Published
Functional observation after morphine withdrawal: effects of SJP-005
A Comparison of the Antinociceptive Properties of SJP-005 and Morphine in Rats
2021
-
December 2020
Intellectual Property Update
US Patent Award No. 10,874,653 for Methods and Compositions to Inhibit Adverse Effects of Vaccinations (SJP-003)
-
October
Licensing Update
Sen-Jam has executed a licensing term sheet with Haltzak Biopharma for SJP-001 (Hangover Prevention) for Colombia with expansion rights to Central and South America.
-
September
Intellectual Property Update
US Patent Award No. 10,765,630 for Methods and Compositions to Treat Enteropathic Arthritis (SJP-004)
-
June
Completed Mentorship program for 2 Northeastern Capstone groups
Sen-Jam wins Life Science Nation Digital RESI Innovation Challenge
-
June
Intellectual Property Update
US Patent Award No. 10,675,261 for Methods and Compositions to Inhibit Dependence of Opioids (SJP-006)
-
May
Selected as Finalist for Life Science Nation Digital RESI Innovation Challenge
Selected as Featured Company for Life Science Nation Digital RESI COVID-19 Solution Presentation
Selected to Present COVID-19 Solution at Biotechnology Innovation Organization (BIO) Digital Conference
Entered Collaborative Partnership Agreement with Assistance Publique - Hopitaux De Paris to Study Treatments for COVID-19
Featured in COVID-19: Treatments before Vaccines Webinar with AdvancedDx Biological Laboratories
-
April
In-Vitro Study underway testing SJP-002 against the COVID-19 virus
Listed on RedCrow’s Equity CrowdFunding site
Sen-Jam featured in StartUp Healths Insights
-
March
Alcohol Hangover Paper Published featuring SJP-001
-
March
Off-Label use of our Opioid Withdrawal Product used in tapering Suboxone
-
January
Sen-Jam participates in StartUp Health Festival during JP Morgan Health Conference2020
-
Fall
Sen-Jam attends RESI conference and pushes greater insight on Opioid Use Disorder
-
November
Presented at Life Science Summit, NYC
-
Fall
Patent issued for SJP-001
-
September
Led panel discussion for Opioid Crisis Working Group -
August
Highlighted in Real Leaders Magazine for work related to opioid withdrawal -
July
Op Ed published in StartUp Health Magazine
-
June
Partnered with Stony Brook University - Center for Biotechnology
-
Spring
Conducted additional pre-clinical studies for opioid withdrawal (SJP-005)
-
January
Sen-Jam participates in StartUp Health Festival, the premier forum of Health Transformers during JP Morgan Health Conference
2019
-
Fall
Sen-Jam attends RESI conference and pushes greater insight on Opioid Use Disorder
-
June
Sen-Jam attends Research Society on Alcoholism Conference
-
May
Sen-Jam attends BioTech event at Cold Spring Harbor Labs
-
Spring
Spring pre-clinical studies for opioid withdrawal (SJP-005)
-
March
Sen-Jam files patent for treatment of enteropathic arthritis (SJP-004)
-
January
Sen-Jam attends JP Morgan Health Conference
2018
-
November
Sen-Jam Wins RESI Innovation Challenge
-
October
Sen-Jam first Corporate Retreat
-
September
Sen-Jam files patents to inhibit symptoms associated with opioid withdrawal (SJP-005), opioid dependence (SJP-006), and opioid tolerance (SJP-007)
-
August
Sen-Jam files patent to inhibit adverse effects associated with vaccinations (SJP-003)
-
August
Sen-Jam Pharmaceutical LLC is formed
-
July
Sen-Jam attends Research Society on Alcoholism Conference
-
June
Investigational New Drug (IND) application opened with the FDA to begin Phase I Clinical Trial
-
June
Sen-Jam files patent to inhibit symptoms associated with Viral Respiratory Infections (SJP-002)
-
April
Sen-Jam presents in Amsterdam at 9th annual Alcohol Hangover Research Group Conference
2017
-
October
Sen-Jam completes Pre-Investigational new drug meeting with FDA
-
August
Trademarks filed & Scientific Advisory Board established
-
June
Sen-Jam presents findings to Alcohol Hangover Research Group at National Institute on Alcohol Abuse and Alcoholism Conference
-
March
Conducted IRB Study for Prevention of Alcohol Hangover (SJP-001)
2016
-
March
Provisional Patents Filed
2015
-
Fall
Volunteer Study Begins—SJP-001
-
Spring
Jackie Iversen has Eureka moment
2014